{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:56:36Z","timestamp":1781538996638,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS-PI17-00547"],"award-info":[{"award-number":["FIS-PI17-00547"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020230","name":"Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades","doi-asserted-by":"publisher","award":["P20_01029"],"award-info":[{"award-number":["P20_01029"]}],"id":[{"id":"10.13039\/100020230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018947","name":"Vicerrectorado de Investigaci\u00f3n y Transferencia, Universidad de Granada","doi-asserted-by":"publisher","award":["xxx"],"award-info":[{"award-number":["xxx"]}],"id":[{"id":"10.13039\/501100018947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Functional stability is crucial for therapeutic proteins at all stages of their lifecycle. Romiplostim (Nplate\u00ae) is world-wide used for treating immune thrombocytopenia purpura. Limited in-use stability data on the proper romiplostim handling is publicly available. This study aimed to evaluate romiplostin in-use functional stability focusing on the interaction with its therapeutic target (TPO-R) and to improve the existing functional assessment strategies by developing a new one using microscale thermophoresis (MST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Reconstituted romiplostim (Nplate\u00ae) samples were analysed. MST and ELISA functional methods were developed and optimized ad hoc to assess romiplostim functional stability. Far-UV-Circular-Dichroism and Intrinsic-Tryptophan-Fluorescence-Spectroscopy were used to ensure MST results by confirming the conformational stability of labelled TPO-R. In-use stability was assessed by subjecting romiplostim to conditions related to hospital handling, e.g. agitation and exposure to natural light; also, freezing and artificial light irradiation were checked as forced degraded condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MST and ELISA were described and validated by their figures of merit. Regarding romiplostim functional stability, both approaches yielded similar stability profiles, but MST detected subtle functional declines that were not revealed by ELISA. Furthermore, MST revealed insights into romiplostim binding stoichiometry, suggesting 1:2 interaction at high concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Regarding functionality, romiplostim was particularly sensitive to light exposure, with less sensitivity to agitation and freezing. These findings also demonstrate that MST serves as new orthogonal strategy to ELISA for assessing functionality, even providing additional data on binding dynamics and stoichiometry. This new MST strategy is applicable for any type of functional study of therapeutic proteins.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-026-04085-5","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:07:14Z","timestamp":1776974834000},"page":"1599-1612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmaceutical Stability of Romiplostim: In-use Functional Study Using Microscale Thermophoresis New Strategy and Elisa"],"prefix":"10.1007","volume":"43","author":[{"given":"Jes\u00fas","family":"Hermosilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Casares-Atienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ruiz-Trav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Torrente-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salmer\u00f3n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cabeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-1430","authenticated-orcid":false,"given":"Natalia","family":"Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"4085_CR1","unstructured":"European Medicines Agency-EMA. Annex I Summary of product characteristics: Nplate [Internet]. 2009. p. 110. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nplate-epar-product-information_en.pdf (Accessed on 27th December 2024)"},{"key":"4085_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/08830185.2021.1960986","volume":"42","author":"D Kandari","year":"2023","unstructured":"Kandari D, Bhatnagar R. Antibody engineering and its therapeutic applications. Int Rev Immunol. 2023;42:156\u201383.","journal-title":"Int Rev Immunol"},{"key":"4085_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.4161\/mabs.21024","volume":"4","author":"G Shimamoto","year":"2012","unstructured":"Shimamoto G, Gegg C, Boone T, Queva C. Peptibodies: a flexible alternative format to antibodies. MAbs. 2012;4:586\u201391.","journal-title":"MAbs"},{"key":"4085_CR4","unstructured":"European Medicines Agency-EMA. ICH Topic Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products [Internet]. ema.europa.eu. 1999. p. 1\u201317. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-6-b-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products-step-5_en.pdf (Accessed 27 December 2024)"},{"key":"4085_CR5","doi-asserted-by":"publisher","DOI":"10.1088\/2050-6120\/ac82a6","volume":"10","author":"S El Deeb","year":"2022","unstructured":"El Deeb S, Al-Harrasi A, Khan A, Al-Broumi M, Al-Thani G, Alomairi M, et al. Microscale thermophoresis as a powerful growing analytical technique for the investigation of biomolecular interaction and the determination of binding parameters. Methods Appl Fluoresc. 2022;10:042001.","journal-title":"Methods Appl Fluoresc"},{"key":"4085_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molstruc.2014.03.009","volume":"1077","author":"M Jerabek-Willemsen","year":"2014","unstructured":"Jerabek-Willemsen M, Andr\u00e9 T, Wanner R, Roth HM, Duhr S, Baaske P, et al. Microscale thermophoresis: interaction analysis and beyond. J Mol Struct. 2014;1077:101\u201313.","journal-title":"J Mol Struct"},{"key":"4085_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17963-1","volume":"7","author":"R Magnez","year":"2017","unstructured":"Magnez R, Thiroux B, Taront S, Segaoula Z, Quesnel B, Thuru X. PD-1\/PD-L1 binding studies using microscale thermophoresis. Sci Rep. 2017;7:17623.","journal-title":"Sci Rep"},{"key":"4085_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147672","volume":"23","author":"R Magnez","year":"2022","unstructured":"Magnez R, Bailly C, Thuru X. Microscale thermophoresis as a tool to study protein interactions and their implication in human diseases. Int J Mol Sci. 2022;23:7672.","journal-title":"Int J Mol Sci"},{"key":"4085_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejpb.2020.10.015","volume":"158","author":"S Indrakumar","year":"2021","unstructured":"Indrakumar S, Zalar M, Tschammer N, Pohl C, N\u00f8rgaard A, Streicher W, et al. Development of a fast screening method for selecting excipients in formulations using MD simulations, NMR and microscale thermophoresis. Eur J Pharm Biopharm. 2021;158:11\u201320.","journal-title":"Eur J Pharm Biopharm"},{"key":"4085_CR10","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1021\/acs.analchem.2c04643","volume":"95","author":"H Yu","year":"2023","unstructured":"Yu H, Zhao Q. DNAzyme-based microscale thermophoresis sensor. Anal Chem. 2023;95:2152\u20136.","journal-title":"Anal Chem"},{"key":"4085_CR11","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1042\/BCJ20200568","volume":"477","author":"MA Contreras","year":"2020","unstructured":"Contreras MA, Macaya L, Neira P, Camacho F, Gonz\u00e1lez A, Acosta J, et al. New insights on the interaction mechanism of rhTNF\u03b1 with its antagonists Adalimumab and Etanercept. Biochem J. 2020;477:3299\u2013311.","journal-title":"Biochem J"},{"key":"4085_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/open.201900167","volume":"8","author":"T Zhang","year":"2019","unstructured":"Zhang T, Nagel\u2010Steger L, Willbold D. Solution\u2010based determination of dissociation constants for the binding of A\u03b242 to antibodies. ChemistryOpen. 2019;8:989\u201394.","journal-title":"ChemistryOpen"},{"key":"4085_CR13","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.xphs.2018.04.005","volume":"107","author":"MR Nejadnik","year":"2018","unstructured":"Nejadnik MR, Randolph TW, Volkin DB, Sch\u00f6neich C, Carpenter JF, Crommelin DJA, et al. Postproduction handling and administration of protein pharmaceuticals and potential instability issues. J Pharm Sci. 2018;107:2013\u20139.","journal-title":"J Pharm Sci"},{"key":"4085_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/pro.4153","volume":"31","author":"AJ Miles","year":"2022","unstructured":"Miles AJ, Ramalli SG, Wallace BA. <scp>DichroWeb<\/scp>, a website for calculating protein secondary structure from circular dichroism spectroscopic data. Protein Sci. 2022;31:37\u201346.","journal-title":"Protein Sci"},{"key":"4085_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1006\/abio.2000.4880","volume":"287","author":"N Sreerama","year":"2000","unstructured":"Sreerama N, Woody RW. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal Biochem. 2000;287:252\u201360.","journal-title":"Anal Biochem"},{"key":"4085_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40259-019-00342-9","volume":"33","author":"J Hermosilla","year":"2019","unstructured":"Hermosilla J, S\u00e1nchez-Mart\u00edn R, P\u00e9rez-Robles R, Salmer\u00f3n-Garc\u00eda A, Casares S, Cabeza J, et al. Comparative stability studies of different Infliximab and biosimilar CT-P13 clinical solutions by combined use of physicochemical analytical techniques and enzyme-linked immunosorbent assay (ELISA). BioDrugs. 2019;33:193\u2013205.","journal-title":"BioDrugs"},{"key":"4085_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59465-7","volume":"10","author":"J Hermosilla","year":"2020","unstructured":"Hermosilla J, P\u00e9rez-Robles R, Salmer\u00f3n-Garc\u00eda A, Casares S, Cabeza J, Bones J, et al. Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation. Sci Rep. 2020;10:2675.","journal-title":"Sci Rep"},{"key":"4085_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jchromb.2016.05.045","volume":"1032","author":"I Su\u00e1rez","year":"2016","unstructured":"Su\u00e1rez I, Salmer\u00f3n-Garc\u00eda A, Cabeza J, Capit\u00e1n-Vallvey LF, Navas N. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies. J Chromatogr B. 2016;1032:155\u201364.","journal-title":"J Chromatogr B"},{"key":"4085_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejpb.2023.12.005","volume":"194","author":"A Torrente-L\u00f3pez","year":"2024","unstructured":"Torrente-L\u00f3pez A, Hermosilla J, Salmer\u00f3n-Garc\u00eda A, Cabeza J, Ruiz-Mart\u00ednez A, Navas N. Comprehensive physicochemical and functional analysis of pembrolizumab based on controlled degradation studies: impact on antigen\u2013antibody binding. Eur J Pharm Biopharm. 2024;194:131\u201347.","journal-title":"Eur J Pharm Biopharm"},{"key":"4085_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","volume":"76","author":"B Wang","year":"2004","unstructured":"Wang B, Nichol J, Sullivan J. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628\u201338.","journal-title":"Clin Pharmacol Ther"},{"key":"4085_CR21","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1023\/B:PHAM.0000003390.51761.3d","volume":"20","author":"B DeSilva","year":"2003","unstructured":"DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20:1885\u2013900.","journal-title":"Pharm Res"},{"key":"4085_CR22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S0731-7085(99)00244-7","volume":"21","author":"JWA Findlay","year":"2000","unstructured":"Findlay JWA, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21:1249\u201373.","journal-title":"J Pharm Biomed Anal"},{"key":"4085_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ijpharm.2018.06.007","volume":"547","author":"DD Shah","year":"2018","unstructured":"Shah DD, Zhang J, Maity H, Mallela KMG. Effect of photo-degradation on the structure, stability, aggregation, and function of an IgG1 monoclonal antibody. Int J Pharm. 2018;547:438\u201349.","journal-title":"Int J Pharm"},{"key":"4085_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2023.101666","volume":"81","author":"AN Arefeva","year":"2023","unstructured":"Arefeva AN, Makarenko IE, Saparova VB, Karal-ogli DD, Afanaseva AN, Dorotenko AR, et al. Comparability of biosimilar romiplostim with originator: protein characterization, animal pharmacodynamics and pharmacokinetics. Biologicals. 2023;81:101666.","journal-title":"Biologicals"},{"key":"4085_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1208\/s12248-010-9234-9","volume":"12","author":"Y-M Wang","year":"2010","unstructured":"Wang Y-M, Krzyzanski W, Doshi S, Xiao JJ, P\u00e9rez-Ruixo JJ, Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010;12:729\u201340.","journal-title":"AAPS J"},{"key":"4085_CR26","unstructured":"European Medicines Agency-EMA. CHMP assessment report for Nplate [Internet]. 2009. p. 59. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/nplate-epar-public-assessment-report_en.pdf (Accessed on 27th December 2024)"},{"key":"4085_CR27","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1039\/C9AN01247H","volume":"144","author":"S Sass","year":"2019","unstructured":"Sass S, St\u00f6cklein WFM, Klevesath A, Hurpin J, Menger M, Hille C. Binding affinity data of DNA aptamers for therapeutic anthracyclines from microscale thermophoresis and surface plasmon resonance spectroscopy. Analyst. 2019;144:6064\u201373.","journal-title":"Analyst"},{"key":"4085_CR28","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0312-3","volume":"21","author":"J Li","year":"2019","unstructured":"Li J, Krause ME, Chen X, Cheng Y, Dai W, Hill JJ, et al. Interfacial stress in the development of biologics: fundamental understanding, current practice, and future perspective. AAPS J. 2019;21:44.","journal-title":"AAPS J"},{"key":"4085_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.57264","volume":"9","author":"I Jarmoskaite","year":"2020","unstructured":"Jarmoskaite I, AlSadhan I, Vaidyanathan PP, Herschlag D. How to measure and evaluate binding affinities. Elife. 2020;9:1\u201334.","journal-title":"Elife"},{"key":"4085_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11095-021-03008-w","volume":"38","author":"YB Yu","year":"2021","unstructured":"Yu YB, Briggs KT, Taraban MB, Brinson RG, Marino JP. Grand challenges in pharmaceutical research series: ridding the cold chain for biologics. Pharm Res. 2021;38:3\u20137.","journal-title":"Pharm Res"},{"key":"4085_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90772-9","volume":"11","author":"K Jain","year":"2021","unstructured":"Jain K, Salamat-Miller N, Taylor K. Freeze\u2013thaw characterization process to minimize aggregation and enable drug product manufacturing of protein based therapeutics. Sci Rep. 2021;11:11332.","journal-title":"Sci Rep"},{"key":"4085_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4161\/mabs.2.1.10787","volume":"2","author":"KL Lazar","year":"2010","unstructured":"Lazar KL, Patapoff TW, Sharma VK. Cold denaturation of monoclonal antibodies. MAbs. 2010;2:42\u201352.","journal-title":"MAbs"},{"key":"4085_CR33","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/bit.10612","volume":"82","author":"E Cao","year":"2003","unstructured":"Cao E, Chen Y, Cui Z, Foster PR. Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions. Biotechnol Bioeng. 2003;82:684\u201390.","journal-title":"Biotechnol Bioeng"},{"key":"4085_CR34","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.xphs.2017.03.019","volume":"106","author":"WJ Rayfield","year":"2017","unstructured":"Rayfield WJ, Kandula S, Khan H, Tugcu N. Impact of freeze\/thaw process on drug substance storage of therapeutics. J Pharm Sci. 2017;106:1944\u201351.","journal-title":"J Pharm Sci"},{"key":"4085_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpb.2015.12.003","volume":"100","author":"A Sreedhara","year":"2016","unstructured":"Sreedhara A, Yin J, Joyce M, Lau K, Wecksler AT, Deperalta G, et al. Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development. Eur J Pharm Biopharm. 2016;100:38\u201346.","journal-title":"Eur J Pharm Biopharm"},{"key":"4085_CR36","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.xphs.2016.01.012","volume":"105","author":"J Hern\u00e1ndez-Jim\u00e9nez","year":"2016","unstructured":"Hern\u00e1ndez-Jim\u00e9nez J, Salmer\u00f3n-Garc\u00eda A, Cabeza J, V\u00e9lez C, Capit\u00e1n-Vallvey LF, Navas N. The Effects of Light-Accelerated Degradation on the Aggregation of Marketed Therapeutic Monoclonal Antibodies Evaluated by Size-Exclusion Chromatography With Diode Array Detection. J Pharm Sci. 2016;105:1405\u201318.","journal-title":"J Pharm Sci"},{"key":"4085_CR37","unstructured":"European Medicines Agency-EMA. ICH Topic Q1B Photostability Testing of New Active Substances and Medicinal Products [Internet]. ema.europa.eu. 1998. p. 9. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-1-b-photostability-testing-new-active-substances-and-medicinal-products-step-5_en.pdf (Accessed 27 December 2024)"},{"key":"4085_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.xphs.2019.10.032","volume":"109","author":"K Traub-Hoffmann","year":"2020","unstructured":"Traub-Hoffmann K, Furtmann B, Laber L, Helm S, Geiger C, Bussemer T. Standardization of the Reconstitution Procedure of Protein Lyophilizates as a Key Parameter to Control Product Stability. J Pharm Sci. 2020;109:211\u20135.","journal-title":"J Pharm Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04085-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04085-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04085-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:30:41Z","timestamp":1781537441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04085-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4085"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04085-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Declaration"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}